C4 Therapeutics, Inc. (CCCC) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
C4 Therapeutics, Inc. (CCCC) Earnings Overview
As of June 29, 2026, C4 Therapeutics, Inc. (CCCC) reported trailing twelve-month net income of -$104M, reflecting +16.4% year-over-year growth. The company earned $-0.82 per diluted share over the past four quarters, with a net profit margin of -292.1%.
Looking at the long-term picture, CCCC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$16M in fiscal 2018.
C4 Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARVN (-$221M net income, -30.8% margin), KYMR (-$315M net income, -794.4% margin), PRAX (-$327M net income), CCCC has room to improve margins relative to the peer group. Compare CCCC vs ARVN →
CCCC Earnings vs Peers
Earnings metrics vs comparable public companies
CCCC Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$105M | +0.3% | -$104M | $-1.27 | -292.1% | -290.7% |
| 2024 | -$105M | +20.5% | -$120M | $-1.52 | -296.0% | -336.1% |
| 2023 | -$132M | -3.4% | -$139M | $-2.67 | -638.3% | -669.8% |
| 2022 | -$128M | -52.8% | -$130M | $-2.62 | -412.2% | -416.6% |
| 2021 | -$84M | -26.5% | -$82M | $-1.82 | -183.2% | -179.4% |
| 2020 | -$66M | -94.5% | -$60M | $-1.54 | -199.8% | -182.1% |
| 2019 | -$34M | -117.0% | -$35M | $-0.79 | -159.5% | -165.8% |
| 2018 | -$16M | - | -$16M | $-1.06 | -81.1% | -84.6% |
Download Data
Export CCCC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CCCC — Frequently Asked Questions
Quick answers to the most common questions about buying CCCC stock.
What is CCCC earnings per share (EPS)?
CCCC trailing twelve-month (TTM) diluted EPS is $-0.82, reflecting +16.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is C4 Therapeutics, Inc.'s net income?
C4 Therapeutics, Inc. (CCCC) trailing twelve-month net income is $-104M as of 2025. Earnings grew +16.4% year-over-year.
Is CCCC profitable?
CCCC is not currently profitable on a TTM basis, reporting a net loss of $-104M. Net margin is -292.1%. Investors should monitor for a return to profitability.
What is CCCC's earnings growth rate?
CCCC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are CCCC's profit margins?
C4 Therapeutics, Inc. net profit margin is -292.1%, operating margin is -290.7%, and gross margin is +77.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is -44.4%.
Is CCCC growing earnings?
Yes, CCCC earnings are accelerating — EPS growth of +16.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-104M. Earnings momentum is strengthening.
What was CCCC's best earnings year?
C4 Therapeutics, Inc.'s highest annual net income on record is $-16M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were CCCC's earnings last quarter?
CCCC's most recent reported quarter was Q1 2026. Net income was $-25M with diluted EPS of $-0.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.